Ariad Pharmaceuticals (NASDAQ:ARIA) has had a rough year, with the stock down over 60% on a variety of bad news for its primary drug Iclusig. More specifically, past issues with blood clots resulted in the drug being pulled from the market and then returned with stronger warnings about side effects.

Many investors remain committed to Ariad and Iclusig's strong efficacy, even with those safety issues now well known. 

In the video below, from Where The Money Is health care analyst David Williamson lays out their argument for Ariad -- and health care analyst Michael Douglass counters with the bear argument and why investing in Ariad may be a mistake.